Lys Therapeutics

Lys Therapeutics is a biotechnology company developing drugs to treat patients suffering from neurovascular or neurodegenerative disorders. The company's main drug is a monoclonal antibody, Glunozumab, displaying an exclusive and groundbreaking mechanism of action, that triggers off-target toxicity through hyperactivation of both vascular and neuronal NMDA receptors (NMDAr). It causes the disruption of the blood-brain and blood-spinal cord barriers and strong neuronal excitotoxicity including stroke and multiple sclerosis.

Lys Therapeutics headquartered in Europe, operates in the Biotechnology, Life Science, Health Care, Medical sector. The company focuses on Biotechnology and has secured $502.1M in funding across 80 round(s). With a team of 1-10 employees, Lys Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Non Equity Assistance - Lys Therapeutics, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.